Comparative Pharmacology
Head-to-head clinical analysis: EVOXAC versus URECHOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOXAC versus URECHOLINE.
EVOXAC vs URECHOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Bethanechol is a synthetic choline ester that directly stimulates muscarinic acetylcholine receptors, primarily M2 and M3 subtypes, leading to increased gastrointestinal motility, bladder contraction, and other parasympathetic effects. It has minimal nicotinic activity.
30 mg orally three times daily.
10-50 mg orally two to four times daily; alternatively, 5 mg subcutaneously three to four times daily. Maximum oral dose: 200 mg daily.
None Documented
None Documented
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Terminal elimination half-life is approximately 1.5-2 hours. Due to its short half-life, continuous or frequent dosing is required for sustained cholinergic effects.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Primarily renal excretion of unchanged drug and metabolites; approximately 50-60% excreted in urine within 24 hours, with negligible biliary or fecal elimination.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist